IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer - Yahoo Finance

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer  Yahoo Finance

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer.



Comments

Post a Comment

Popular posts from this blog

“63 Signs You May Have Long COVID | Eat This Not That - Eat This, Not That” plus 3 more

Image
“63 Signs You May Have Long COVID | Eat This Not That - Eat This, Not That” plus 3 more 63 Signs You May Have Long COVID | Eat This Not That - Eat This, Not That Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures - American Academy of Pediatrics An afternoon nap could improve your cognitive abilities, study says - Arizona Daily Star Sharp pain when breathing in: Chest, ribs, causes, and more - Medical News Today 63 Signs You May Have Long COVID | Eat This Not That - Eat This, Not That Posted: 16 Jan 2021 12:00 AM PST A few months into the COVID-19 pandemic, health experts noticed that some people who battled the virus—mild, moderate, and severe infections included—weren't recovering from it. In fact, they reported lingering symptoms that increased in severity after their initial infection had cleared. For long haulers, "it is certainly clear that for around 1...
Read more

“Diagnosis and management of acute respiratory distress syndrome - CMAJ” plus 2 more

Image
“Diagnosis and management of acute respiratory distress syndrome - CMAJ” plus 2 more Diagnosis and management of acute respiratory distress syndrome - CMAJ Underlying illness, respiratory infection raise risk for severe COVID in kids - CIDRAP COPD lung sounds: Types, descriptions, treatment, and more - Medical News Today Diagnosis and management of acute respiratory distress syndrome - CMAJ Posted: 25 May 2021 12:00 AM PDT KEY POINTS Acute respiratory distress syndrome (ARDS) can arise from a variety of causes, and manifests clinically as acute hypoxemic respiratory failure, characterized by acute, diffuse, inflammatory lung injury that leads to increased alveolar capillary permeability and development of nonhydrostatic pulmonary edema. Clinical diagnosis of ARDS is made on the basis of the Berlin definition, with severity of the disease and prognosis for survival based on the degree of hypoxemia. ...
Read more